Ankaferd blood stopper as a new strategy to avoid early complications after transradial procedures: A randomized clinical trial

Görgülü, Şevket; Norgaz, Tugrul; Sipahi, İlke

doi:10.1111/joic.12514

Cited by 5 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Our present study disclosed that antithrombin effect of ABS is linked to the high iron content of the drug. Ankaferd hemostat has already been tested in numerous controlled randomized clinical trials, such as in the fields of Cardiology and Cardiovascular Surgery, [5][6][7] demonstrating its antihemorrhagic effects devoid of thrombosis. The results of our present investigation showed up the underlying ABS mechanism that the absence of clinical thrombosis is because of the antithrombin effects of the drug that could be ascribed to its high iron content.…”

mentioning

confidence: 99%

The Antithrombin Effect of Ankaferd Hemostat (ABS) Is Related to the High Iron Content of the Medicine

Okay

Öztürk

Haznedaroğlu

2019

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

mentioning

confidence: 99%

The Antithrombin Effect of Ankaferd Hemostat (ABS) Is Related to the High Iron Content of the Medicine

Okay

Öztürk

Haznedaroğlu

2019

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

“…However, an example of a clinical study can be given as follows, even if it is not used for this purpose in Turkey: Euphorbia peplus was tried directly for basal cell carcinoma, intraepidermal carcinoma or squamous cell carcinoma in Phase I/II clinical study [2]. Some herbs, such as the use of No side-effects were noted during the study [61] Calendula officinalis for radiotherapy or lumpectomy or mastectomy wounds, have also been tried to prevent skin problems that may develop due to cancer treatment [41,42]. Another example, Pistacia terebinthus was tried in metastatic colorectal patients who developed skin toxicity while receiving first-line cetuximab in combination with chemotherapy [57].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of clinical trials of the plants, which have ethnobotanical uses for skin disorders in Turkey: a review

et al. 2021

View full text Add to dashboard Cite

Background Ethnobotanical studies investigating a large number of traditional herbs and uses have an important role in the discovery of new drugs. Nowadays, some of these traditional herbs are researched directly in the clinical trials. In this study, it is aimed to evaluate the 19 plant species that have been identified in the clinical trials among 300 plant species belonging to 79 families with traditional use for skin problems in Turkey. Main body Natural sources are very important to treat diseases for thousands of years. The ethnopharmacological research of natural products ranges from the collection of biogenic samples such as plants to preclinical and clinical studies with the aim of developing drug templates or new drugs. In the ethnopharmacological approach, it is aimed to reach the result based on the traditional and modern knowledge about natural resources. The biggest advantage of this approach is synthesizing new and old information. After the plant or natural compound is determined, other processes work similarly with conventional drugs. Methods Ethnobotanical papers, thesis and projects in Istanbul University Faculty of Pharmacy Department of Pharmaceutical Botany and databases (PubMed and Google Scholar) have been sought and results were synthesized. Results Most of the clinical uses of herbs have been seen similar to their traditional uses. On the other hand, there are some plants on which their clinical uses differ from the traditional uses such as Borago officinalis, Calendula officinalis or Euphorbia peplus. When the frequency of traditional uses of herbs are compared, Plantago species, Plantago major and Plantago lanceolata are the most used taxa in Turkey, secondly, Hypericum perforatum comes. However, Plantago species are not of much interest in clinical trials. It is seen that most of the plants in the clinical research are tried for wound healing occuring due to different origins such as cancer, surgery and injury. Side effects were observed only during the application of Allium cepa, Cydonia oblonga and H. perforatum. Conclusions When clinical trials are evaluated in terms of efficacy and overall results, significant differences and effective results are seen in treatment groups given herbs in comparison with placebo or control groups.

show abstract

“…Gorgulu et al 27 ABS was compared with formocresol for 3, 6, and 12 months for pain, swelling, mobility, resorption, furcation, and periapical bone destruction. ABS was as effective as formocresol for a pulp dressing of primary molar.…”

Section: Patients Undergoing Coronary Angiographymentioning

confidence: 99%

Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)

et al. 2020

View full text Add to dashboard Cite

Ankaferd hemostat (Ankaferd blood stopper [ABS], Istanbul, Turkey) is a hemostatic agent affecting red blood cell-fibrinogen interactions. ABS has been traditionally used in Anatolia as a hemostatic agent for centuries. ABS contains a standardized combination of the plants namely Glycyrrhiza glabra, Thymus vulgaris, Alpinia officinarum, Vitis vinifera, and Urtica dioica. The hemostatic effect of ABS depends upon the quick promotion of a protein network, particularly fibrinogen gamma, in relation to the erythrocyte aggregation. The aim of this review is to indicate pharmacobiological basis and clinical backgrounds of ABS. Current perspective for using ABS is to provide hemostasis and accelerating wound healing particularly in cases which are difficult to manage. Future controlled trials are needed to elucidate the actions of ABS with in hemostasis, antithrombotic, anti-inflammatory, anti-infective, antifungal, and anti-oxidative effects.

show abstract

Ankaferd blood stopper as a new strategy to avoid early complications after transradial procedures: A randomized clinical trial

Abstract: Ankaferd blood stopper is a promising device for use in patent hemostasis, with no evidence on RAO at short-term or long term and with reduced risk of re-bleeding at the end of hemostasis.

Cited by 5 publications

References 25 publications

The Antithrombin Effect of Ankaferd Hemostat (ABS) Is Related to the High Iron Content of the Medicine

The Antithrombin Effect of Ankaferd Hemostat (ABS) Is Related to the High Iron Content of the Medicine

Evaluation of clinical trials of the plants, which have ethnobotanical uses for skin disorders in Turkey: a review

Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)

Contact Info

Product

Resources

About